Company Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages.
The company was incorporated in 2014 and is headquartered in Milan, Italy.
| Country | Italy |
| Founded | 2014 |
| IPO Date | Dec 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Pierluigi Paracchi |
Contact Details
Address: Olgettina, No. 58 Milan, L6 20132 Italy | |
| Phone | 39-02-2643-6639 |
| Website | genenta.com |
Stock Details
| Ticker Symbol | GNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.50 |
| CIK Code | 0001838716 |
| CUSIP Number | 36870W100 |
| ISIN Number | US36870W1009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pierluigi Paracchi | Vice Chairman of the Board, Chief Executive Officer and GM |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder and Chairman of the Executive Scientific Board |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder and Member of the Executive Scientific Board |
| Richard B. Slansky | Chief Financial Officer |
| Dr. Carlo Russo M.D. | Chief Medical Officer and Head of Development |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development |
| Barbara Regonini | Director of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 20-F/A | Filing |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 20, 2023 | 6-K | Report of foreign issuer |
| Jun 14, 2023 | 6-K | Report of foreign issuer |
| May 24, 2023 | EFFECT | Notice of Effectiveness |
| May 12, 2023 | F-3 | Filing |